Publications & Reports

Lipopolysaccharide, immune activation and liver abnormalities in HIV-HBV co-infected individuals on HBV-active combination antiretroviral therapy.

Crane M, Avihingsanon A, Rajasuriar R, Velayudham P, Iser D, Solomon A, Sebolao B, Tran A, Spelman T, Matthews G, Cameron P, Tangkijvanich P, Dore GJ, Ruxrungtham K, Lewin SR
Monash University, Melbourne, Victoria.


We investigated the relationship between microbial translocation, immune activation and liver disease in HIV-HBV co-infection. Lipopolysaccharide (LPS), soluble (s)CD14, CXCL10 and CCL-2 were elevated in HIV-HBV co-infection and declined following HBV-active combination antiretroviral therapy (cART) but CXCL10 remained elevated. No markers were associated with liver disease severity on liver biopsy (n=96) but CXCL10, IL-6, IL-10, TNFa and IFNg were all associated with elevated liver enzymes on HBV-active cART. Stimulation of hepatocyte cell lines in vitro with IFNg and LPS induced a profound synergistic increase in production of CXCL10. LPS may contribute to liver disease via stimulating persistent production of CXCL10.

Full text unformatted version of manuscript available using link on bottom right of this page.

Publisher’s final pdf available at


  • Journal: The Journal of Infectious Diseases
  • Published: 28/02/2014
  • Volume: 210
  • Issue: 5
  • Pagination: 745-751


Health Issues